Alimera Sciences (NASDAQ:ALIM) Stock Rating Lowered by StockNews.com

Alimera Sciences (NASDAQ:ALIM) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Separately, Maxim Group initiated coverage on Alimera Sciences in a report on Monday, March 25th. They set a “buy” rating and a $10.00 price target for the company.

Alimera Sciences Stock Down 6.0 %

NASDAQ:ALIM opened at $3.46 on Tuesday. Alimera Sciences has a twelve month low of $1.56 and a twelve month high of $4.38. The firm has a market capitalization of $181.13 million, a price-to-earnings ratio of -1.60 and a beta of 1.18. The company has a quick ratio of 2.31, a current ratio of 2.39 and a debt-to-equity ratio of 1.40. The stock’s 50 day moving average price is $3.73 and its two-hundred day moving average price is $3.65.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09). The firm had revenue of $26.31 million for the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same period last year, the company posted ($0.54) earnings per share. Equities research analysts expect that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Institutional Trading of Alimera Sciences

Institutional investors have recently bought and sold shares of the business. Stonepine Capital Management LLC boosted its stake in shares of Alimera Sciences by 0.4% in the fourth quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after buying an additional 15,773 shares during the period. Worth Venture Partners LLC acquired a new position in Alimera Sciences in the 3rd quarter valued at $1,840,000. Finally, AIGH Capital Management LLC bought a new stake in shares of Alimera Sciences during the 3rd quarter valued at $7,355,000. Institutional investors own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).